Bioorthogonal Probes for Polo-like Kinase 1 Imaging and Quantification

Center for Systems Biology, Massachusetts General Hospital, Boston, MA 02114, USA.
Angewandte Chemie International Edition (Impact Factor: 11.26). 09/2011; 50(40):9378-81. DOI: 10.1002/anie.201103273
Source: PubMed


Click inside: A nuclear protein target, polo-like kinase 1 (PLK1) was imaged using a biocompatible bioorthogonal ligation between a specific drug and a fluorescent dye in live cells (see picture). Colocalization of the dye and the protein target was confirmed by antibody staining and by expressing a GFP construct of PLK1. The two-step PLK1 imaging procedure was used to quantify PLK1 expression levels in cancer cell lines of various tissue origins.

Download full-text


Available from: Katy Yang, Mar 03, 2015
  • Source
    • "Since the advent of intravital imaging, it has been possible to perform single cell and population analysis of tumor biology in vivo. In recent years, these methods have also been adapted to the study of drug pharmacology [1], [2], which has been in part enabled by commercially available compounds as well as a growing number of fluorescently labeled therapeutic companion drugs [3]–[6]. To fully realize the potential of this imaging approach, however, and to maximize the data that can be mined in a reasonable time frame, it will be necessary to overcome several challenges. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent advances in the field of intravital imaging have for the first time allowed us to conduct pharmacokinetic and pharmacodynamic studies at the single cell level in live animal models. Due to these advances, there is now a critical need for automated analysis of pharmacokinetic data. To address this, we began by surveying common thresholding methods to determine which would be most appropriate for identifying fluorescently labeled drugs in intravital imaging. We then developed a segmentation algorithm that allows semi-automated analysis of pharmacokinetic data at the single cell level. Ultimately, we were able to show that drug concentrations can indeed be extracted from serial intravital imaging in an automated fashion. We believe that the application of this algorithm will be of value to the analysis of intravital microscopy imaging particularly when imaging drug action at the single cell level.
    PLoS ONE 04/2013; 8(4):e60988. DOI:10.1371/journal.pone.0060988 · 3.23 Impact Factor
  • Source
    • "Increasingly, reactive fluorochromes and quantum dots are being employed to label antibodies and other proteins. Newer fluorochromes (Budin et al., 2011; Reiner et al., 2010) are now available, with increased cell permeability, biocompatibility, and optimized pharmacokinetics for efficient in vivo use. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Until recently, the idea of observing life deep within the tissues of a living mouse, at a resolution sufficient to pick out cellular behaviors and molecular signals underlying them, remained a much-coveted dream. Now, a new era of intravital fluorescence microscopy has dawned. In this Primer, we review the technologies that made this revolution possible and demonstrate how intravital imaging is beginning to provide quantitative and dynamic insights into cell biology, immunology, tumor biology, and neurobiology.
    Cell 11/2011; 147(5):983-91. DOI:10.1016/j.cell.2011.11.004 · 32.24 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Responses to molecularly targeted therapies can be highly variable and depend on mutations, fluctuations in target protein levels in individual cells, and drug delivery. The ability to rapidly quantitate drug response in cells harvested from patients in a point-of-care setting would have far reaching implications. Capitalizing on recent developments with miniaturized NMR technologies, we have developed a magnetic nanoparticle-based approach to directly measure both target expression and drug binding in scant human cells. The method involves covalent conjugation of the small-molecule drug to a magnetic nanoparticle that is then used as a read-out for target expression and drug-binding affinity. Using poly(ADP-ribose) polymerase (PARP) inhibition as a model system, we developed an approach to distinguish differential expression of PARP in scant cells with excellent correlation to gold standards, the ability to mimic drug pharmacodynamics ex vivo through competitive target-drug binding, and the potential to perform such measurements in clinical samples.
    ACS Nano 10/2011; 5(11):9216-24. DOI:10.1021/nn203450p · 12.88 Impact Factor
Show more